{"id":"https://openalex.org/W2512864147","doi":"https://doi.org/10.1097/md.0000000000004529","title":"Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD): A PRISMA-compliant systematic review and network meta-analysis","display_name":"Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD): A PRISMA-compliant systematic review and network meta-analysis","alternate_titles":[],"publication_year":2016,"publication_date":"2016-08-01","ids":{"openalex":"https://openalex.org/W2512864147","doi":"https://doi.org/10.1097/md.0000000000004529","mag":"2512864147","pmid":"https://pubmed.ncbi.nlm.nih.gov/27512874","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/4985329"},"language":"en","primary_location":{"id":"doi:10.1097/md.0000000000004529","doi":"https://doi.org/10.1097/md.0000000000004529","is_oa":true,"landing_page_url":"https://doi.org/10.1097/md.0000000000004529","pdf_url":null,"source":{"id":"https://openalex.org/S28966261","display_name":"Medicine","issn_l":"0025-7974","issn":["0025-7974","1536-5964"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310318547","host_organization_name":"Wolters Kluwer","host_organization_lineage":["https://openalex.org/P4310318547"],"host_organization_lineage_names":["Wolters Kluwer"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Medicine","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2512864147"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1097/md.0000000000004529","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5008250919","display_name":"Ratree Sawangjit","orcid":"https://orcid.org/0000-0002-6868-4336","observed_orcids":["https://orcid.org/0000-0002-6868-4336"]},"institutions":[{"id":"https://openalex.org/I11662577","display_name":"Monash University Malaysia","ror":"https://ror.org/00yncr324","country_code":"MY","type":"education","lineage":["https://openalex.org/I11662577","https://openalex.org/I56590836"]},{"id":"https://openalex.org/I123096312","display_name":"Mahasarakham University","ror":"https://ror.org/0453j3c58","country_code":"TH","type":"education","lineage":["https://openalex.org/I123096312"]},{"id":"https://openalex.org/I1332387789","display_name":"Siriraj Hospital","ror":"https://ror.org/0331zs648","country_code":"TH","type":"healthcare","lineage":["https://openalex.org/I1332387789"]},{"id":"https://openalex.org/I135310074","display_name":"University of Wisconsin\u2013Madison","ror":"https://ror.org/01y2jtd41","country_code":"US","type":"education","lineage":["https://openalex.org/I135310074"]},{"id":"https://openalex.org/I165143802","display_name":"The University of Queensland","ror":"https://ror.org/00rqy9422","country_code":"AU","type":"education","lineage":["https://openalex.org/I165143802"]},{"id":"https://openalex.org/I25399158","display_name":"Mahidol University","ror":"https://ror.org/01znkr924","country_code":"TH","type":"education","lineage":["https://openalex.org/I25399158"]},{"id":"https://openalex.org/I4210140007","display_name":"Ramathibodi Hospital","ror":"https://ror.org/04884sy85","country_code":"TH","type":"healthcare","lineage":["https://openalex.org/I4210140007"]},{"id":"https://openalex.org/I66200439","display_name":"Naresuan University","ror":"https://ror.org/03e2qe334","country_code":"TH","type":"education","lineage":["https://openalex.org/I66200439"]}],"countries":["AU","MY","TH","US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Ratree Sawangjit","raw_affiliation_strings":["Clinical Pharmacy Research Unit (CPRU), Department of Clinical Pharmacy, Faculty of Pharmacy, Mahasarakham University, Mahasarakham, Thailand School of Pharmacy, Monash University Malaysia, Selangor, Malaysia Center of Pharmaceutical Outcomes Research, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok Center of Health Outcome Research and Therapeutic Safety, School of Pharmaceutical Sciences,University of Phayao, Phayao Section for Clinical Epidemiology and Biostatistics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand Liver Care Network and Organ Care Research, Swedish Medical Center, Seattle School of Pharmacy, University of Wisconsin, Madison, WI School of Population Health, University of Queensland, Brisbane, QLD, Australia","Acquisition of data: RS, BC","Analysis and interpretation of data: RS, SS, BC, AT, KVK, NC","Approval of the final manuscript: RS, SS, BC, PP, AT, KVK, NC","Critical revision of the manuscript for important intellectual content: RS, SS, BC, PP, AT, KVK, NC","Drafting of the manuscript: RS, NC, AT","RS, BC, PP, SS, AT, and NC declare no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years","Review registration: PROSPERO CRD 42015025051","Study concept and design: RS, PP, NC, AT","Supplemental Digital Content is available for this article","Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (www.md-journal.com)","no other relationships or activities that could appear to have influenced the submitted work. KVK has received support for research related to NASH from Gilead Sciences, Galectin Pharmaceuticals, Intercept, Immuron, Tobira, Mochida and NGM BioPharma and has served as a paid advisor to Intercept, Enanta, Verlyx, and Gilead Sciences, and also been a consultant of Gilead Sciences"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Pharmacy Research Unit (CPRU), Department of Clinical Pharmacy, Faculty of Pharmacy, Mahasarakham University, Mahasarakham, Thailand School of Pharmacy, Monash University Malaysia, Selangor, Malaysia Center of Pharmaceutical Outcomes Research, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok Center of Health Outcome Research and Therapeutic Safety, School of Pharmaceutical Sciences,University of Phayao, Phayao Section for Clinical Epidemiology and Biostatistics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand Liver Care Network and Organ Care Research, Swedish Medical Center, Seattle School of Pharmacy, University of Wisconsin, Madison, WI School of Population Health, University of Queensland, Brisbane, QLD, Australia","institution_ids":["https://openalex.org/I11662577","https://openalex.org/I123096312","https://openalex.org/I1332387789","https://openalex.org/I135310074","https://openalex.org/I165143802","https://openalex.org/I25399158","https://openalex.org/I4210140007","https://openalex.org/I66200439"]},{"raw_affiliation_string":"Acquisition of data: RS, BC","institution_ids":[]},{"raw_affiliation_string":"Analysis and interpretation of data: RS, SS, BC, AT, KVK, NC","institution_ids":[]},{"raw_affiliation_string":"Approval of the final manuscript: RS, SS, BC, PP, AT, KVK, NC","institution_ids":[]},{"raw_affiliation_string":"Critical revision of the manuscript for important intellectual content: RS, SS, BC, PP, AT, KVK, NC","institution_ids":[]},{"raw_affiliation_string":"Drafting of the manuscript: RS, NC, AT","institution_ids":[]},{"raw_affiliation_string":"RS, BC, PP, SS, AT, and NC declare no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years","institution_ids":[]},{"raw_affiliation_string":"Review registration: PROSPERO CRD 42015025051","institution_ids":[]},{"raw_affiliation_string":"Study concept and design: RS, PP, NC, AT","institution_ids":[]},{"raw_affiliation_string":"Supplemental Digital Content is available for this article","institution_ids":[]},{"raw_affiliation_string":"Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (www.md-journal.com)","institution_ids":[]},{"raw_affiliation_string":"no other relationships or activities that could appear to have influenced the submitted work. KVK has received support for research related to NASH from Gilead Sciences, Galectin Pharmaceuticals, Intercept, Immuron, Tobira, Mochida and NGM BioPharma and has served as a paid advisor to Intercept, Enanta, Verlyx, and Gilead Sciences, and also been a consultant of Gilead Sciences","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045918374","display_name":"Bunchai Chongmelaxme","orcid":"https://orcid.org/0000-0002-7750-6961","observed_orcids":["https://orcid.org/0000-0002-7750-6961"]},"institutions":[{"id":"https://openalex.org/I66200439","display_name":"Naresuan University","ror":"https://ror.org/03e2qe334","country_code":"TH","type":"education","lineage":["https://openalex.org/I66200439"]}],"countries":["TH"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Bunchai Chongmelaxme","raw_affiliation_strings":["Center of Pharmaceutical Outcomes Research, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok","Acquisition of data: RS, BC","Analysis and interpretation of data: RS, SS, BC, AT, KVK, NC","Approval of the final manuscript: RS, SS, BC, PP, AT, KVK, NC","Critical revision of the manuscript for important intellectual content: RS, SS, BC, PP, AT, KVK, NC","Drafting of the manuscript: RS, NC, AT","RS, BC, PP, SS, AT, and NC declare no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years","Review registration: PROSPERO CRD 42015025051","Study concept and design: RS, PP, NC, AT","Supplemental Digital Content is available for this article","Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (www.md-journal.com)","no other relationships or activities that could appear to have influenced the submitted work. KVK has received support for research related to NASH from Gilead Sciences, Galectin Pharmaceuticals, Intercept, Immuron, Tobira, Mochida and NGM BioPharma and has served as a paid advisor to Intercept, Enanta, Verlyx, and Gilead Sciences, and also been a consultant of Gilead Sciences"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center of Pharmaceutical Outcomes Research, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok","institution_ids":["https://openalex.org/I66200439"]},{"raw_affiliation_string":"Acquisition of data: RS, BC","institution_ids":[]},{"raw_affiliation_string":"Analysis and interpretation of data: RS, SS, BC, AT, KVK, NC","institution_ids":[]},{"raw_affiliation_string":"Approval of the final manuscript: RS, SS, BC, PP, AT, KVK, NC","institution_ids":[]},{"raw_affiliation_string":"Critical revision of the manuscript for important intellectual content: RS, SS, BC, PP, AT, KVK, NC","institution_ids":[]},{"raw_affiliation_string":"Drafting of the manuscript: RS, NC, AT","institution_ids":[]},{"raw_affiliation_string":"RS, BC, PP, SS, AT, and NC declare no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years","institution_ids":[]},{"raw_affiliation_string":"Review registration: PROSPERO CRD 42015025051","institution_ids":[]},{"raw_affiliation_string":"Study concept and design: RS, PP, NC, AT","institution_ids":[]},{"raw_affiliation_string":"Supplemental Digital Content is available for this article","institution_ids":[]},{"raw_affiliation_string":"Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (www.md-journal.com)","institution_ids":[]},{"raw_affiliation_string":"no other relationships or activities that could appear to have influenced the submitted work. KVK has received support for research related to NASH from Gilead Sciences, Galectin Pharmaceuticals, Intercept, Immuron, Tobira, Mochida and NGM BioPharma and has served as a paid advisor to Intercept, Enanta, Verlyx, and Gilead Sciences, and also been a consultant of Gilead Sciences","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058993607","display_name":"Pochamana Phisalprapa","orcid":"https://orcid.org/0000-0003-1995-4405","observed_orcids":["https://orcid.org/0000-0003-1995-4405"]},"institutions":[{"id":"https://openalex.org/I1332387789","display_name":"Siriraj Hospital","ror":"https://ror.org/0331zs648","country_code":"TH","type":"healthcare","lineage":["https://openalex.org/I1332387789"]},{"id":"https://openalex.org/I25399158","display_name":"Mahidol University","ror":"https://ror.org/01znkr924","country_code":"TH","type":"education","lineage":["https://openalex.org/I25399158"]}],"countries":["TH"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Pochamana Phisalprapa","raw_affiliation_strings":["Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok","Acquisition of data: RS, BC","Analysis and interpretation of data: RS, SS, BC, AT, KVK, NC","Approval of the final manuscript: RS, SS, BC, PP, AT, KVK, NC","Critical revision of the manuscript for important intellectual content: RS, SS, BC, PP, AT, KVK, NC","Drafting of the manuscript: RS, NC, AT","RS, BC, PP, SS, AT, and NC declare no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years","Review registration: PROSPERO CRD 42015025051","Study concept and design: RS, PP, NC, AT","Supplemental Digital Content is available for this article","Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (www.md-journal.com)","no other relationships or activities that could appear to have influenced the submitted work. KVK has received support for research related to NASH from Gilead Sciences, Galectin Pharmaceuticals, Intercept, Immuron, Tobira, Mochida and NGM BioPharma and has served as a paid advisor to Intercept, Enanta, Verlyx, and Gilead Sciences, and also been a consultant of Gilead Sciences"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok","institution_ids":["https://openalex.org/I1332387789","https://openalex.org/I25399158"]},{"raw_affiliation_string":"Acquisition of data: RS, BC","institution_ids":[]},{"raw_affiliation_string":"Analysis and interpretation of data: RS, SS, BC, AT, KVK, NC","institution_ids":[]},{"raw_affiliation_string":"Approval of the final manuscript: RS, SS, BC, PP, AT, KVK, NC","institution_ids":[]},{"raw_affiliation_string":"Critical revision of the manuscript for important intellectual content: RS, SS, BC, PP, AT, KVK, NC","institution_ids":[]},{"raw_affiliation_string":"Drafting of the manuscript: RS, NC, AT","institution_ids":[]},{"raw_affiliation_string":"RS, BC, PP, SS, AT, and NC declare no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years","institution_ids":[]},{"raw_affiliation_string":"Review registration: PROSPERO CRD 42015025051","institution_ids":[]},{"raw_affiliation_string":"Study concept and design: RS, PP, NC, AT","institution_ids":[]},{"raw_affiliation_string":"Supplemental Digital Content is available for this article","institution_ids":[]},{"raw_affiliation_string":"Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (www.md-journal.com)","institution_ids":[]},{"raw_affiliation_string":"no other relationships or activities that could appear to have influenced the submitted work. KVK has received support for research related to NASH from Gilead Sciences, Galectin Pharmaceuticals, Intercept, Immuron, Tobira, Mochida and NGM BioPharma and has served as a paid advisor to Intercept, Enanta, Verlyx, and Gilead Sciences, and also been a consultant of Gilead Sciences","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062702667","display_name":"Surasak Saokaew","orcid":"https://orcid.org/0000-0002-1382-0660","observed_orcids":["https://orcid.org/0000-0002-1382-0660"]},"institutions":[{"id":"https://openalex.org/I11662577","display_name":"Monash University Malaysia","ror":"https://ror.org/00yncr324","country_code":"MY","type":"education","lineage":["https://openalex.org/I11662577","https://openalex.org/I56590836"]},{"id":"https://openalex.org/I4210090662","display_name":"University of Phayao","ror":"https://ror.org/00a5mh069","country_code":"TH","type":"education","lineage":["https://openalex.org/I4210090662"]},{"id":"https://openalex.org/I66200439","display_name":"Naresuan University","ror":"https://ror.org/03e2qe334","country_code":"TH","type":"education","lineage":["https://openalex.org/I66200439"]}],"countries":["MY","TH"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Surasak Saokaew","raw_affiliation_strings":["Center of Health Outcome Research and Therapeutic Safety, School of Pharmaceutical Sciences,University of Phayao, Phayao","Center of Pharmaceutical Outcomes Research, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok","School of Pharmacy, Monash University Malaysia, Selangor, Malaysia","Acquisition of data: RS, BC","Analysis and interpretation of data: RS, SS, BC, AT, KVK, NC","Approval of the final manuscript: RS, SS, BC, PP, AT, KVK, NC","Critical revision of the manuscript for important intellectual content: RS, SS, BC, PP, AT, KVK, NC","Drafting of the manuscript: RS, NC, AT","RS, BC, PP, SS, AT, and NC declare no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years","Review registration: PROSPERO CRD 42015025051","Study concept and design: RS, PP, NC, AT","Supplemental Digital Content is available for this article","Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (www.md-journal.com)","no other relationships or activities that could appear to have influenced the submitted work. KVK has received support for research related to NASH from Gilead Sciences, Galectin Pharmaceuticals, Intercept, Immuron, Tobira, Mochida and NGM BioPharma and has served as a paid advisor to Intercept, Enanta, Verlyx, and Gilead Sciences, and also been a consultant of Gilead Sciences"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center of Health Outcome Research and Therapeutic Safety, School of Pharmaceutical Sciences,University of Phayao, Phayao","institution_ids":["https://openalex.org/I4210090662"]},{"raw_affiliation_string":"Center of Pharmaceutical Outcomes Research, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok","institution_ids":["https://openalex.org/I66200439"]},{"raw_affiliation_string":"School of Pharmacy, Monash University Malaysia, Selangor, Malaysia","institution_ids":["https://openalex.org/I11662577"]},{"raw_affiliation_string":"Acquisition of data: RS, BC","institution_ids":[]},{"raw_affiliation_string":"Analysis and interpretation of data: RS, SS, BC, AT, KVK, NC","institution_ids":[]},{"raw_affiliation_string":"Approval of the final manuscript: RS, SS, BC, PP, AT, KVK, NC","institution_ids":[]},{"raw_affiliation_string":"Critical revision of the manuscript for important intellectual content: RS, SS, BC, PP, AT, KVK, NC","institution_ids":[]},{"raw_affiliation_string":"Drafting of the manuscript: RS, NC, AT","institution_ids":[]},{"raw_affiliation_string":"RS, BC, PP, SS, AT, and NC declare no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years","institution_ids":[]},{"raw_affiliation_string":"Review registration: PROSPERO CRD 42015025051","institution_ids":[]},{"raw_affiliation_string":"Study concept and design: RS, PP, NC, AT","institution_ids":[]},{"raw_affiliation_string":"Supplemental Digital Content is available for this article","institution_ids":[]},{"raw_affiliation_string":"Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (www.md-journal.com)","institution_ids":[]},{"raw_affiliation_string":"no other relationships or activities that could appear to have influenced the submitted work. KVK has received support for research related to NASH from Gilead Sciences, Galectin Pharmaceuticals, Intercept, Immuron, Tobira, Mochida and NGM BioPharma and has served as a paid advisor to Intercept, Enanta, Verlyx, and Gilead Sciences, and also been a consultant of Gilead Sciences","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056464791","display_name":"Ammarin Thakkinstian","orcid":"https://orcid.org/0000-0001-9991-386X","observed_orcids":["https://orcid.org/0000-0001-9991-386X"]},"institutions":[{"id":"https://openalex.org/I25399158","display_name":"Mahidol University","ror":"https://ror.org/01znkr924","country_code":"TH","type":"education","lineage":["https://openalex.org/I25399158"]},{"id":"https://openalex.org/I4210140007","display_name":"Ramathibodi Hospital","ror":"https://ror.org/04884sy85","country_code":"TH","type":"healthcare","lineage":["https://openalex.org/I4210140007"]}],"countries":["TH"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Ammarin Thakkinstian","raw_affiliation_strings":["Section for Clinical Epidemiology and Biostatistics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand","Acquisition of data: RS, BC","Analysis and interpretation of data: RS, SS, BC, AT, KVK, NC","Approval of the final manuscript: RS, SS, BC, PP, AT, KVK, NC","Critical revision of the manuscript for important intellectual content: RS, SS, BC, PP, AT, KVK, NC","Drafting of the manuscript: RS, NC, AT","RS, BC, PP, SS, AT, and NC declare no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years","Review registration: PROSPERO CRD 42015025051","Study concept and design: RS, PP, NC, AT","Supplemental Digital Content is available for this article","Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (www.md-journal.com)","no other relationships or activities that could appear to have influenced the submitted work. KVK has received support for research related to NASH from Gilead Sciences, Galectin Pharmaceuticals, Intercept, Immuron, Tobira, Mochida and NGM BioPharma and has served as a paid advisor to Intercept, Enanta, Verlyx, and Gilead Sciences, and also been a consultant of Gilead Sciences"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Section for Clinical Epidemiology and Biostatistics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand","institution_ids":["https://openalex.org/I25399158","https://openalex.org/I4210140007"]},{"raw_affiliation_string":"Acquisition of data: RS, BC","institution_ids":[]},{"raw_affiliation_string":"Analysis and interpretation of data: RS, SS, BC, AT, KVK, NC","institution_ids":[]},{"raw_affiliation_string":"Approval of the final manuscript: RS, SS, BC, PP, AT, KVK, NC","institution_ids":[]},{"raw_affiliation_string":"Critical revision of the manuscript for important intellectual content: RS, SS, BC, PP, AT, KVK, NC","institution_ids":[]},{"raw_affiliation_string":"Drafting of the manuscript: RS, NC, AT","institution_ids":[]},{"raw_affiliation_string":"RS, BC, PP, SS, AT, and NC declare no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years","institution_ids":[]},{"raw_affiliation_string":"Review registration: PROSPERO CRD 42015025051","institution_ids":[]},{"raw_affiliation_string":"Study concept and design: RS, PP, NC, AT","institution_ids":[]},{"raw_affiliation_string":"Supplemental Digital Content is available for this article","institution_ids":[]},{"raw_affiliation_string":"Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (www.md-journal.com)","institution_ids":[]},{"raw_affiliation_string":"no other relationships or activities that could appear to have influenced the submitted work. KVK has received support for research related to NASH from Gilead Sciences, Galectin Pharmaceuticals, Intercept, Immuron, Tobira, Mochida and NGM BioPharma and has served as a paid advisor to Intercept, Enanta, Verlyx, and Gilead Sciences, and also been a consultant of Gilead Sciences","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091028785","display_name":"Kris V. Kowdley","orcid":"https://orcid.org/0000-0002-8553-3652","observed_orcids":["https://orcid.org/0000-0002-8553-3652"]},"institutions":[{"id":"https://openalex.org/I4210092087","display_name":"Swedish Medical Center","ror":"https://ror.org/00f5bva59","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210092087"]},{"id":"https://openalex.org/I4210093417","display_name":"Swedish Medical Center","ror":"https://ror.org/004jktf35","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210093417","https://openalex.org/I94396219"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Kris V. Kowdley","raw_affiliation_strings":["Liver Care Network and Organ Care Research, Swedish Medical Center, Seattle","Acquisition of data: RS, BC","Analysis and interpretation of data: RS, SS, BC, AT, KVK, NC","Approval of the final manuscript: RS, SS, BC, PP, AT, KVK, NC","Critical revision of the manuscript for important intellectual content: RS, SS, BC, PP, AT, KVK, NC","Drafting of the manuscript: RS, NC, AT","RS, BC, PP, SS, AT, and NC declare no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years","Review registration: PROSPERO CRD 42015025051","Study concept and design: RS, PP, NC, AT","Supplemental Digital Content is available for this article","Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (www.md-journal.com)","no other relationships or activities that could appear to have influenced the submitted work. KVK has received support for research related to NASH from Gilead Sciences, Galectin Pharmaceuticals, Intercept, Immuron, Tobira, Mochida and NGM BioPharma and has served as a paid advisor to Intercept, Enanta, Verlyx, and Gilead Sciences, and also been a consultant of Gilead Sciences"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Liver Care Network and Organ Care Research, Swedish Medical Center, Seattle","institution_ids":["https://openalex.org/I4210092087","https://openalex.org/I4210093417"]},{"raw_affiliation_string":"Acquisition of data: RS, BC","institution_ids":[]},{"raw_affiliation_string":"Analysis and interpretation of data: RS, SS, BC, AT, KVK, NC","institution_ids":[]},{"raw_affiliation_string":"Approval of the final manuscript: RS, SS, BC, PP, AT, KVK, NC","institution_ids":[]},{"raw_affiliation_string":"Critical revision of the manuscript for important intellectual content: RS, SS, BC, PP, AT, KVK, NC","institution_ids":[]},{"raw_affiliation_string":"Drafting of the manuscript: RS, NC, AT","institution_ids":[]},{"raw_affiliation_string":"RS, BC, PP, SS, AT, and NC declare no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years","institution_ids":[]},{"raw_affiliation_string":"Review registration: PROSPERO CRD 42015025051","institution_ids":[]},{"raw_affiliation_string":"Study concept and design: RS, PP, NC, AT","institution_ids":[]},{"raw_affiliation_string":"Supplemental Digital Content is available for this article","institution_ids":[]},{"raw_affiliation_string":"Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (www.md-journal.com)","institution_ids":[]},{"raw_affiliation_string":"no other relationships or activities that could appear to have influenced the submitted work. KVK has received support for research related to NASH from Gilead Sciences, Galectin Pharmaceuticals, Intercept, Immuron, Tobira, Mochida and NGM BioPharma and has served as a paid advisor to Intercept, Enanta, Verlyx, and Gilead Sciences, and also been a consultant of Gilead Sciences","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5013349830","display_name":"Nathorn Chaiyakunapruk","orcid":"https://orcid.org/0000-0003-4572-8794","observed_orcids":["https://orcid.org/0000-0003-4572-8794","https://orcid.org/0000-0001-6213-722X"]},"institutions":[{"id":"https://openalex.org/I11662577","display_name":"Monash University Malaysia","ror":"https://ror.org/00yncr324","country_code":"MY","type":"education","lineage":["https://openalex.org/I11662577","https://openalex.org/I56590836"]},{"id":"https://openalex.org/I135310074","display_name":"University of Wisconsin\u2013Madison","ror":"https://ror.org/01y2jtd41","country_code":"US","type":"education","lineage":["https://openalex.org/I135310074"]},{"id":"https://openalex.org/I165143802","display_name":"The University of Queensland","ror":"https://ror.org/00rqy9422","country_code":"AU","type":"education","lineage":["https://openalex.org/I165143802"]},{"id":"https://openalex.org/I66200439","display_name":"Naresuan University","ror":"https://ror.org/03e2qe334","country_code":"TH","type":"education","lineage":["https://openalex.org/I66200439"]}],"countries":["AU","MY","TH","US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Nathorn Chaiyakunapruk","raw_affiliation_strings":["Center of Pharmaceutical Outcomes Research, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok","School of Pharmacy, Monash University Malaysia, Selangor, Malaysia","School of Pharmacy, University of Wisconsin, Madison, WI","School of Population Health, University of Queensland, Brisbane, QLD, Australia","Acquisition of data: RS, BC","Analysis and interpretation of data: RS, SS, BC, AT, KVK, NC","Approval of the final manuscript: RS, SS, BC, PP, AT, KVK, NC","Critical revision of the manuscript for important intellectual content: RS, SS, BC, PP, AT, KVK, NC","Drafting of the manuscript: RS, NC, AT","Nathorn Chaiyakunapruk, School of Pharmacy, Monash University Malaysia, Jalan Lagoon Selatan, 46150 Bandar Sunway, Selangor, Malaysia (e-mail: [email\u00a0protected])","RS, BC, PP, SS, AT, and NC declare no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years","Review registration: PROSPERO CRD 42015025051","Study concept and design: RS, PP, NC, AT","Supplemental Digital Content is available for this article","Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (www.md-journal.com)","no other relationships or activities that could appear to have influenced the submitted work. KVK has received support for research related to NASH from Gilead Sciences, Galectin Pharmaceuticals, Intercept, Immuron, Tobira, Mochida and NGM BioPharma and has served as a paid advisor to Intercept, Enanta, Verlyx, and Gilead Sciences, and also been a consultant of Gilead Sciences"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center of Pharmaceutical Outcomes Research, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok","institution_ids":["https://openalex.org/I66200439"]},{"raw_affiliation_string":"School of Pharmacy, Monash University Malaysia, Selangor, Malaysia","institution_ids":["https://openalex.org/I11662577"]},{"raw_affiliation_string":"School of Pharmacy, University of Wisconsin, Madison, WI","institution_ids":["https://openalex.org/I135310074"]},{"raw_affiliation_string":"School of Population Health, University of Queensland, Brisbane, QLD, Australia","institution_ids":["https://openalex.org/I165143802"]},{"raw_affiliation_string":"Acquisition of data: RS, BC","institution_ids":[]},{"raw_affiliation_string":"Analysis and interpretation of data: RS, SS, BC, AT, KVK, NC","institution_ids":[]},{"raw_affiliation_string":"Approval of the final manuscript: RS, SS, BC, PP, AT, KVK, NC","institution_ids":[]},{"raw_affiliation_string":"Critical revision of the manuscript for important intellectual content: RS, SS, BC, PP, AT, KVK, NC","institution_ids":[]},{"raw_affiliation_string":"Drafting of the manuscript: RS, NC, AT","institution_ids":[]},{"raw_affiliation_string":"Nathorn Chaiyakunapruk, School of Pharmacy, Monash University Malaysia, Jalan Lagoon Selatan, 46150 Bandar Sunway, Selangor, Malaysia (e-mail: [email\u00a0protected])","institution_ids":["https://openalex.org/I11662577"]},{"raw_affiliation_string":"RS, BC, PP, SS, AT, and NC declare no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years","institution_ids":[]},{"raw_affiliation_string":"Review registration: PROSPERO CRD 42015025051","institution_ids":[]},{"raw_affiliation_string":"Study concept and design: RS, PP, NC, AT","institution_ids":[]},{"raw_affiliation_string":"Supplemental Digital Content is available for this article","institution_ids":[]},{"raw_affiliation_string":"Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (www.md-journal.com)","institution_ids":[]},{"raw_affiliation_string":"no other relationships or activities that could appear to have influenced the submitted work. KVK has received support for research related to NASH from Gilead Sciences, Galectin Pharmaceuticals, Intercept, Immuron, Tobira, Mochida and NGM BioPharma and has served as a paid advisor to Intercept, Enanta, Verlyx, and Gilead Sciences, and also been a consultant of Gilead Sciences","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":4,"institutions_distinct_count":11,"corresponding_author_ids":["https://openalex.org/A5013349830"],"corresponding_institution_ids":["https://openalex.org/I11662577","https://openalex.org/I135310074","https://openalex.org/I165143802","https://openalex.org/I66200439"],"apc_list":{"value":1950,"currency":"USD","value_usd":1950},"apc_paid":{"value":1950,"currency":"USD","value_usd":1950},"fwci":3.575,"has_fulltext":true,"cited_by_count":67,"citation_normalized_percentile":{"value":0.93660931,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":92,"max":99},"biblio":{"volume":"95","issue":"32","first_page":"e4529","last_page":"e4529"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10351","display_name":"Liver Disease Diagnosis and Treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2721","display_name":"Hepatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10351","display_name":"Liver Disease Diagnosis and Treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2721","display_name":"Hepatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11834","display_name":"Liver Diseases and Immunity","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2721","display_name":"Hepatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10966","display_name":"Liver physiology and pathology","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2721","display_name":"Hepatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/non-alcoholic-fatty-liver-disease","display_name":"non-alcoholic fatty liver disease","score":1.0},{"id":"https://openalex.org/keywords/nafld-treatment","display_name":"NAFLD treatment","score":0.703000009059906},{"id":"https://openalex.org/keywords/obeticholic-acid","display_name":"obeticholic acid","score":0.8939999938011169},{"id":"https://openalex.org/keywords/pentoxifylline","display_name":"pentoxifylline","score":0.9919999837875366},{"id":"https://openalex.org/keywords/thiazolidinediones","display_name":"thiazolidinediones","score":0.996999979019165},{"id":"https://openalex.org/keywords/vitamin-e","display_name":"vitamin E","score":0.9879999756813049},{"id":"https://openalex.org/keywords/metformin","display_name":"metformin","score":0.6759999990463257},{"id":"https://openalex.org/keywords/liver-fibrosis","display_name":"liver fibrosis","score":0.8840000033378601},{"id":"https://openalex.org/keywords/non-alcoholic-steatohepatitis","display_name":"nonalcoholic steatohepatitis","score":0.906000018119812},{"id":"https://openalex.org/keywords/steatosis","display_name":"steatosis","score":0.7509999871253967},{"id":"https://openalex.org/keywords/liver-cirrhosis","display_name":"liver cirrhosis","score":0.8849999904632568},{"id":"https://openalex.org/keywords/all-cause-mortality","display_name":"all-cause mortality","score":0.8640000224113464},{"id":"https://openalex.org/keywords/comparative-efficacy","display_name":"drug efficacy comparison","score":0.492000013589859}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9523730874061584},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.7399802803993225},{"id":"https://openalex.org/C2776954865","wikidata":"https://www.wikidata.org/wiki/Q1546498","display_name":"Nonalcoholic fatty liver disease","level":4,"score":0.6670356392860413},{"id":"https://openalex.org/C2777067796","wikidata":"https://www.wikidata.org/wiki/Q15708271","display_name":"Obeticholic acid","level":4,"score":0.5377400517463684},{"id":"https://openalex.org/C2777214474","wikidata":"https://www.wikidata.org/wiki/Q147778","display_name":"Cirrhosis","level":2,"score":0.5337321162223816},{"id":"https://openalex.org/C95190672","wikidata":"https://www.wikidata.org/wiki/Q815382","display_name":"Meta-analysis","level":2,"score":0.5278993248939514},{"id":"https://openalex.org/C2778772119","wikidata":"https://www.wikidata.org/wiki/Q6058862","display_name":"Fatty liver","level":3,"score":0.48855075240135193},{"id":"https://openalex.org/C2780323712","wikidata":"https://www.wikidata.org/wiki/Q19484","display_name":"Metformin","level":3,"score":0.47706830501556396},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4097346067428589},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.285791277885437},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.0},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.0},{"id":"https://openalex.org/C2779306644","wikidata":"https://www.wikidata.org/wiki/Q2002370","display_name":"Insulin","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000975","descriptor_name":"Antioxidants","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D002635","descriptor_name":"Chenodeoxycholic Acid","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D002635","descriptor_name":"Chenodeoxycholic Acid","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010431","descriptor_name":"Pentoxifylline","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D014810","descriptor_name":"Vitamin E","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D045162","descriptor_name":"Thiazolidinediones","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D065626","descriptor_name":"Non-alcoholic Fatty Liver Disease","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true}],"locations_count":3,"locations":[{"id":"doi:10.1097/md.0000000000004529","doi":"https://doi.org/10.1097/md.0000000000004529","is_oa":true,"landing_page_url":"https://doi.org/10.1097/md.0000000000004529","pdf_url":null,"source":{"id":"https://openalex.org/S28966261","display_name":"Medicine","issn_l":"0025-7974","issn":["0025-7974","1536-5964"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310318547","host_organization_name":"Wolters Kluwer","host_organization_lineage":["https://openalex.org/P4310318547"],"host_organization_lineage_names":["Wolters Kluwer"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Medicine","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:4985329","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4985329/","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4985329/pdf/","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Medicine (Baltimore)","raw_type":"Text"},{"id":"pmid:27512874","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/27512874","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Medicine","raw_type":"Comparative Study"}],"best_oa_location":{"id":"doi:10.1097/md.0000000000004529","doi":"https://doi.org/10.1097/md.0000000000004529","is_oa":true,"landing_page_url":"https://doi.org/10.1097/md.0000000000004529","pdf_url":null,"source":{"id":"https://openalex.org/S28966261","display_name":"Medicine","issn_l":"0025-7974","issn":["0025-7974","1536-5964"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310318547","host_organization_name":"Wolters Kluwer","host_organization_lineage":["https://openalex.org/P4310318547"],"host_organization_lineage_names":["Wolters Kluwer"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Medicine","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/systematic-review","display_name":"Systematic Review"},{"id":"https://openalex.org/study-designs/meta-analysis","display_name":"Meta-Analysis"}],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2512864147.pdf","grobid_xml":"https://content.openalex.org/works/W2512864147.grobid-xml"},"referenced_works_count":81,"referenced_works":["https://openalex.org/W278816506","https://openalex.org/W1523312932","https://openalex.org/W1617328014","https://openalex.org/W1623910198","https://openalex.org/W1645656667","https://openalex.org/W1856151485","https://openalex.org/W1866142084","https://openalex.org/W1868475579","https://openalex.org/W1908780918","https://openalex.org/W1963683487","https://openalex.org/W1968396962","https://openalex.org/W1968969864","https://openalex.org/W1969342962","https://openalex.org/W1970224691","https://openalex.org/W1973401573","https://openalex.org/W1976571856","https://openalex.org/W1980245616","https://openalex.org/W1981844352","https://openalex.org/W1988200914","https://openalex.org/W1990055069","https://openalex.org/W1995988129","https://openalex.org/W1996415443","https://openalex.org/W1997425045","https://openalex.org/W2007516026","https://openalex.org/W2019810874","https://openalex.org/W2021182659","https://openalex.org/W2022296797","https://openalex.org/W2022394079","https://openalex.org/W2022693320","https://openalex.org/W2025680761","https://openalex.org/W2028160831","https://openalex.org/W2034509216","https://openalex.org/W2037467390","https://openalex.org/W2040557955","https://openalex.org/W2044206844","https://openalex.org/W2048913262","https://openalex.org/W2049633956","https://openalex.org/W2057787549","https://openalex.org/W2059196301","https://openalex.org/W2060963949","https://openalex.org/W2062618014","https://openalex.org/W2062812115","https://openalex.org/W2065655717","https://openalex.org/W2067740038","https://openalex.org/W2068129913","https://openalex.org/W2071550553","https://openalex.org/W2077653789","https://openalex.org/W2079167765","https://openalex.org/W2080725795","https://openalex.org/W2086158879","https://openalex.org/W2086657341","https://openalex.org/W2087829753","https://openalex.org/W2096064097","https://openalex.org/W2097677758","https://openalex.org/W2098689751","https://openalex.org/W2100093159","https://openalex.org/W2103156933","https://openalex.org/W2106061083","https://openalex.org/W2106768039","https://openalex.org/W2107328434","https://openalex.org/W2107453802","https://openalex.org/W2108868101","https://openalex.org/W2114090706","https://openalex.org/W2115415903","https://openalex.org/W2116393673","https://openalex.org/W2116528307","https://openalex.org/W2119912578","https://openalex.org/W2135400982","https://openalex.org/W2138306815","https://openalex.org/W2139112405","https://openalex.org/W2144625636","https://openalex.org/W2151490108","https://openalex.org/W2152925891","https://openalex.org/W2153032268","https://openalex.org/W2154075360","https://openalex.org/W2155798268","https://openalex.org/W2157338541","https://openalex.org/W2157671355","https://openalex.org/W2314791836","https://openalex.org/W2316193238","https://openalex.org/W2413809816"],"related_works":["https://openalex.org/W1866142084","https://openalex.org/W2896906661","https://openalex.org/W4392751953","https://openalex.org/W4361202479","https://openalex.org/W2542212316","https://openalex.org/W3197627254","https://openalex.org/W2602328838","https://openalex.org/W4291142841","https://openalex.org/W4310742002","https://openalex.org/W2025680761"],"abstract_inverted_index":{"BACKGROUND:":[0],"The":[1],"prevalence":[2],"of":[3,18,36,41,55,60,96,106,133,150,167,187,199,213,218,240,261],"nonalcoholic":[4],"fatty":[5],"liver":[6,74],"disease":[7],"(NAFLD)":[8],"has":[9],"significantly":[10,126,175],"increased":[11],"over":[12],"the":[13,27,58,122],"last":[14],"decades.":[15],"Despite":[16],"existence":[17],"several":[19],"interventions,":[20],"there":[21],"remains":[22],"unclear":[23],"which":[24],"interventions":[25,56],"work":[26],"best.":[28],"METHODS:":[29],"A":[30,84,104],"systematic":[31],"review":[32],"and":[33,53,82,157,172,183,230,243],"network":[34,85,270],"meta-analysis":[35,86],"randomized":[37],"trials":[38],"comparing":[39],"efficacy":[40,52,239],"all":[42],"treatment":[43],"options":[44],"in":[45,57,162,165,246,250],"NAFLD":[46],"were":[47,65,112,216],"performed":[48],"to":[49,68,89,202,267],"determine":[50],"comparative":[51],"safety":[54],"management":[59],"NAFLD.":[61,251],"Several":[62],"electronic":[63],"databases":[64],"searched":[66],"up":[67],"Nov":[69],"15,":[70],"2015.":[71],"Outcomes":[72],"include":[73],"histological":[75,210],"outcomes":[76,178,221],"(i.e.,":[77,193],"fibrosis),":[78],"all-cause":[79],"mortality,":[80],"cirrhosis,":[81,223],"safety.":[83],"was":[87,98,121],"applied":[88],"estimate":[90],"pooled":[91],"risk":[92],"ratios":[93],"(RR).":[94],"Quality":[95,186],"evidence":[97,188],"assessed":[99],"using":[100],"GRADE":[101],"criteria.":[102],"RESULTS:":[103],"total":[105],"44":[107],"studies":[108,264],"(n":[109],"=":[110],"3802)":[111],"eligible.":[113],"When":[114],"compared":[115],"with":[116,129,146],"placebo,":[117],"obeticholic":[118],"acid":[119],"(OCA)":[120],"only":[123],"intervention":[124],"that":[125],"improved":[127,141,176],"fibrosis":[128,142],"RR":[130,147],"(95%":[131,148],"CI)":[132,149],"1.91":[134],"(1.15,":[135],"3.16),":[136],"while":[137,169],"pentoxyfylline":[138],"(PTX)":[139],"demonstrated":[140],"without":[143],"statistical":[144],"significance":[145],"2.27":[151],"(0.81,":[152],"6.36).":[153],"Only":[154],"thiazolidinedione":[155],"(TZD)":[156],"vitamin":[158,173,206,244],"E":[159,174,207,245],"use":[160],"resulted":[161],"significant":[163],"increase":[164],"resolution":[166],"NASH,":[168],"OCA,":[170,241],"TZD,":[171,205,242],"other":[177],"including":[179],"NAS,":[180],"steatosis,":[181],"ballooning,":[182],"inflammation":[184],"outcomes.":[185],"varied":[189],"from":[190],"very":[191],"low":[192],"metformin,":[194],"PTX":[195],"on":[196,208,257],"mean":[197],"change":[198],"ballooning":[200],"grade)":[201],"high":[203],"(OCA,":[204],"improving":[209,247],"outcomes).":[211],"Limitations":[212],"this":[214,269],"study":[215,228,236],"lack":[217],"relevant":[219],"long-term":[220],"(e.g.,":[222],"death,":[224],"safety),":[225],"possible":[226],"small":[227,259],"effect,":[229],"few":[231],"head-to-head":[232],"studies.":[233,262],"CONCLUSIONS:":[234],"Our":[235],"suggests":[237],"potential":[238],"histologic":[248],"endpoints":[249],"These":[252],"findings":[253],"are":[254,265],"however":[255],"based":[256],"a":[258],"number":[260],"Additional":[263],"awaited":[266],"strengthen":[268],"meta-analysis.":[271]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2512864147","counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":4},{"year":2023,"cited_by_count":8},{"year":2022,"cited_by_count":8},{"year":2021,"cited_by_count":10},{"year":2020,"cited_by_count":8},{"year":2019,"cited_by_count":5},{"year":2018,"cited_by_count":7},{"year":2017,"cited_by_count":10},{"year":2015,"cited_by_count":2}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2016-09-16T00:00:00"}
